Company profile
Vistagen Therapeutics, Inc.
NASDAQ:VTGNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AV-101 | phase2 | — | 4 | completed, unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06809179 | phase2 | recruiting | 2025-01-09 | 2026-04-01 | VistaGen Therapeutics, Inc. | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder |
| NCT04147949 | phase2 | unknown | 2022-08-01 | 2023-12-01 | VistaGen Therapeutics, Inc. | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia |
| NCT05280054 | phase1 | unknown | 2021-12-23 | 2022-09-01 | VistaGen Therapeutics, Inc. | AV-101 Alone and in Combination With Probenecid in Healthy Subjects |
| NCT03078322 | phase2 | completed | 2018-03-05 | 2019-10-01 | VistaGen Therapeutics, Inc. | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression |
| NCT06358651 | phase3 | active_not_recruiting | 2024-03-28 | 2025-10-31 | VistaGen Therapeutics, Inc. | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) |
FDA applications (0)
No records yet.